At a glance
- Originator Merz Pharma
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 06 Jul 1995 Discontinued-II for Atherosclerosis in Germany (Unknown route)
- 06 Jul 1995 Discontinued-II for Hyperlipidaemia in Germany (Unknown route)